97 related articles for article (PubMed ID: 6848203)
21. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance.
Piekoszewski W; Chow FS; Jusko WJ
Drug Metab Dispos; 1993; 21(4):690-8. PubMed ID: 7690698
[TBL] [Abstract][Full Text] [Related]
22. Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.
Buck M; Kovach JS
Cancer Chemother Pharmacol; 1985; 15(1):40-3. PubMed ID: 4006048
[TBL] [Abstract][Full Text] [Related]
23. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.
Dorr RT; Peng YM; Alberts DS
Invest New Drugs; 1984; 2(4):351-7. PubMed ID: 6096286
[TBL] [Abstract][Full Text] [Related]
24. Directed intravascular precipitation of bisantrene for pelvic malignant lesions: preclinical studies.
Lieber MM; Welch TJ; Johnson CM; Farrow GM; Buck M; Kovach JS
Mayo Clin Proc; 1986 Mar; 61(3):173-9. PubMed ID: 3945117
[TBL] [Abstract][Full Text] [Related]
25. Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.
Powis G
J Chromatogr; 1981 Dec; 226(2):514-20. PubMed ID: 7320182
[No Abstract] [Full Text] [Related]
26. Phase II trial of bisantrene in advanced colorectal carcinoma.
Ahmed T; Kemeny NE; Michaelson RA; Harper HD
Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
[TBL] [Abstract][Full Text] [Related]
28. The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit.
Taylor SM; Rodgers RM; Lynn RK; Gerber N
J Pharmacol Exp Ther; 1980 May; 213(2):289-99. PubMed ID: 7365688
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of bisantrene in advanced colorectal cancer: a cancer and leukemia group B study.
Perry MC; Forastiere AA; Richards F; Weiss RB; Anbar D
Cancer Treat Rep; 1982 Nov; 66(11):1997-8. PubMed ID: 7139643
[No Abstract] [Full Text] [Related]
30. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
Spiegel RJ; Blum RH; Levin M; Pinto CA; Wernz JC; Speyer JL; Hoffman KS; Muggia FM
Cancer Res; 1982 Jan; 42(1):354-8. PubMed ID: 7053862
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog.
Lu K; Loo TL
Cancer Res; 1980 May; 40(5):1427-30. PubMed ID: 7370981
[TBL] [Abstract][Full Text] [Related]
32. Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice.
Sauer JM; Bao J; Smith RL; Kuester RK; Mayersohn M; Sipes IG
Drug Metab Dispos; 1997 Oct; 25(10):1184-90. PubMed ID: 9321522
[TBL] [Abstract][Full Text] [Related]
33. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
34. Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes.
Murdock KC; Child RG; Lin Y; Warren JD; Fabio PF; Lee VJ; Izzo PT; Lang SA; Angier RB; Citarella RV; Wallace RE; Durr FE
J Med Chem; 1982 May; 25(5):505-18. PubMed ID: 6806475
[TBL] [Abstract][Full Text] [Related]
35. N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity.
Murdock KC; Lee VJ; Citarella RV; Durr FE; Nicolau G; Kohlbrenner M
J Med Chem; 1993 Jul; 36(15):2098-101. PubMed ID: 8340913
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological studies on 5-methoxymethyl-2'-deoxyuridine: a new antiviral agent.
Meldrum JB; Gupta VS; Taneja AK; Sisodia CS
J Pharmacol Exp Ther; 1981 Feb; 216(2):275-80. PubMed ID: 7463349
[TBL] [Abstract][Full Text] [Related]
37. Experimental infusion phlebitis: tolerance pH of peripheral vein.
Kuwahara T; Asanami S; Kawauchi Y; Kubo S
J Toxicol Sci; 1999 May; 24(2):113-21. PubMed ID: 10349613
[TBL] [Abstract][Full Text] [Related]
38. Relationship between pharmacokinetics and pharmacodynamics of fazadinium in rabbits.
Dominguez-Gil AA; Cepeda M; Muriel C; Calvo JI; Dominguez-Gil A; Alonso AC
Arzneimittelforschung; 1981; 31(11):1913-7. PubMed ID: 6119095
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
